5 completed, 1 not yet recruiting, 1 withdrawn. 5 Phase 2, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Not yet recruiting 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Stage IIC Melanoma: new trials by email Literature Review of Stage IIC Melanoma trials Research Report on Stage IIC Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Pembrolizumab in Patients With High Risk, Stage IIB/IIC Cutaneous Melanoma: a Single Arm Proof of Concept Phase IIA Study. Pembrolizumab neoadjuvant treatment, surgery, Adjuvant treatment - Stage IIB Melanoma, Stage IIC Melanoma | Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Besancon | 19 | 2026-11-01 | 2026-10-20 |
| Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery Montanide ISA 51 VG, MART-1 antigen, laboratory biomarker analysis - Recurrent Melanoma, Stage IIA Melanoma | Early Phase 1 | Completed | Mayo Clinic | 30 | 2012-10-01 | 2018-10-09 |
| Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma sargramostim, sentinel lymph node biopsy, laboratory biomarker analysis - Stage IB Melanoma, Stage IIA Melanoma | Phase 3 | Withdrawn | Jonsson Comprehensive Cancer Center | 2011-08-05 | 2020-07-27 | |
| Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery saracatinib - Recurrent Melanoma, Stage IIA Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2006-07-01 | 2014-05-21 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma tyrosinase peptide, gp100 antigen, MART-1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2004-06-01 | 2015-04-15 |
| Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Completed | University of Southern California | 42 | 2004-05-01 | 2014-05-22 |
| Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma HPV 16 E7:12-20, gp100:209-217(210M), laboratory biomarker analysis - Recurrent Melanoma, Stage IA Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 36 | 1999-04-01 | 2017-02-20 |
Melanoma (7) · Uveal Melanoma (2)
Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms by Site (7) · Neoplasms, Germ Cell and Embryonal (7) · Neoplasms, Nerve Tissue (7) · Neuroectodermal Tumors (7) · Neuroendocrine Tumors (7) · Nevi and Melanomas (7) · Skin Diseases (7) · Skin Neoplasms (7) · Skin and Connective Tissue Diseases (7) · Eye Diseases (2) · Eye Neoplasms (2) · Uveal Diseases (2) · Uveal Neoplasms (2)
montanide ISA 51 (3) · MART-1 Antigen (2) · incomplete Freund's adjuvant (2) · sargramostim (2) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · MAGEA3 protein, human (1) · ProMune (1) · S 28463 (1) · Saline Solution, Hypertonic (1) · Sentinel Lymph Node Biopsy (1) · Surgical Procedures, Operative (1) · gp100 Melanoma Antigen (1) · resiquimod (1) · saracatinib (1)
National Cancer Institute (NCI) (3) · Centre Hospitalier Universitaire de Besancon (1) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1) · University of Southern California (1)
United States (6) · France (1)
Jeffrey Weber (2) · Richard Essner (1) · Svetomir Markovic, M.D., Ph.D. (1) · Thomas Gajewski (1) · Walter J. Urba, MD, PhD (1)
N01CM62201 (1), R01CA120228 (1), R21CA082614 (1)